IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial (Q34795777)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q19859634)
(Q47265013)
(P304) 1516-1523
(P407) (Q1860)
(P433) 11
(P478) 67
(P577) Monday, July 14, 2008
(P921) (Q269829)
(Q6934595)
(Q181600)
(Q18032037)
(Q187255)
(Q425154)
(Q108853737)
(P1433) (Q4767876)
(P1476) "IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial" (language: en)
(P2093) E Keystone
H P Tony
A Cantagrel
A Sanchez
E Alecock
J Lee
J Kremer
(P2860) (Q28295371)
(Q37049629)
(Q38459919)
(Q34687703)
(Q36732112)
(Q35954629)
(Q35953268)
(Q34574857)
(Q35605643)
(Q36561156)
(Q34896269)
(Q40379276)
(Q40384995)
(Q35995900)
(Q34347054)
(Q37286418)
(Q35834922)
(Q34759478)
(Q24568204)
(Q34283776)
(Q28214986)
(Q24801010)
(Q34275961)
(Q34220191)
(Q34071253)
(Q24531184)
(Q36400353)
(Q35547301)
(Q55049410)
(Q45235877)
(Q52853837)
(Q44774931)
(Q46919825)
(Q53864394)
(Q45004490)
(Q44930010)
(Q44432142)
(Q57232023)
(Q57751326)
(Q74615622)
(Q73895634)
(Q78116880)
(Q80201780)
(Q80340995)
other details